Nasdaq · CIK 0000882796
BCRX BIOCRYST PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 39 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at BIOCRYST PHARMACEUTICALS INC, scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 2Weak | sell10b5-1 | Nancy J Hutson director | $53k | 7,000 | -7% | - |
Congressional trades
2 trades in BCRX disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Jul 10, 2026 | 56 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Nov 13, 2025 | 32 days after the trade |
Transactions
The last 31 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Amy E McKee director | AGrant or award Common Stock | +644 | $9.70 | $6,247 | 47,821 | 39 d ago |
| Aug 31, 2026 | Vincent Milano director | AGrant or award Common Stock | +1,159 | $9.70 | $11k | 109,642 | 39 d ago |
| Aug 31, 2026 | Jill C. Milne director | AGrant or award Common Stock | +1,288 | $9.70 | $12k | 33,226 | 39 d ago |
| Aug 31, 2026 | Jon P Stonehouse President & CEO | AGrant or award Common Stock | +644 | $9.70 | $6,247 | 1,340,419 | 39 d ago |
| Aug 31, 2026 | Steven Frank director | AGrant or award Common Stock | +1,288 | $9.70 | $12k | 36,747 | 39 d ago |
| Feb 28, 2025 | Vincent Milano director | AGrant or award Common Stock | +653 | $8.61 | $5,622 | 76,737 | Mar 4, 2025 |
| Dec 19, 2024 | Anthony Doyle Chief Financial Officer | AGrant or award Common Stock | +120,700 | $0.00 | $0 | 380,328 | Dec 23, 2024 |
| Dec 19, 2024 | Charles K Gayer Chief Commercial Officer | AGrant or award Common Stock | +125,950 | $0.00 | $0 | 426,007 | Dec 23, 2024 |
| Dec 19, 2024 | Helen M. Thackray Chief R&D Officer | AGrant or award Common Stock | +125,950 | $0.00 | $0 | 390,939 | Dec 23, 2024 |
| Dec 19, 2024 | Alane P Barnes Chief Legal Officer | AGrant or award Common Stock | +120,700 | $0.00 | $0 | 415,190 | Dec 23, 2024 |
| Dec 19, 2024 | Jon P Stonehouse President & CEO | AGrant or award Common Stock | +362,100 | $0.00 | $0 | 1,463,119 | Dec 23, 2024 |
| Dec 19, 2024 | Jon P Stonehouse President & CEO | FTax withholding Common Stock | -14,010 | $7.39 | $104k | 1,449,109 | Dec 23, 2024 |
| Dec 19, 2024 | Alane P Barnes Chief Legal Officer | FTax withholding Common Stock | -2,461 | $7.39 | $18k | 412,729 | Dec 23, 2024 |
| Dec 19, 2024 | Anthony Doyle Chief Financial Officer | FTax withholding Common Stock | -2,461 | $7.39 | $18k | 377,867 | Dec 23, 2024 |
| Dec 19, 2024 | Helen M. Thackray Chief R&D Officer | FTax withholding Common Stock | -6,096 | $7.39 | $45k | 384,843 | Dec 23, 2024 |
| Dec 19, 2024 | Charles K Gayer Chief Commercial Officer | FTax withholding Common Stock | -2,461 | $7.39 | $18k | 423,546 | Dec 23, 2024 |
| Dec 19, 2024 | Alane P Barnes Chief Legal Officer | AGrant or award Emp. Stock Option (Right to Buy)derivative | +250,100 | $0.00 | $0 | 250,100 | Dec 23, 2024 |
| Dec 19, 2024 | Anthony Doyle Chief Financial Officer | AGrant or award Emp. Stock Option (Right to Buy)derivative | +250,100 | $0.00 | $0 | 250,100 | Dec 23, 2024 |
| Dec 19, 2024 | Helen M. Thackray Chief R&D Officer | AGrant or award Emp. Stock Option (Right to Buy)derivative | +260,950 | $0.00 | $0 | 260,950 | Dec 23, 2024 |
| Dec 20, 2024 | Jon P Stonehouse President & CEO | GGift Common Stock | -20,000 | $0.00 | $0 | 1,429,109 | Dec 23, 2024 |
| Dec 19, 2024 | Charles K Gayer Chief Commercial Officer | AGrant or award Emp. Stock Option (Right to Buy)derivative | +260,950 | $0.00 | $0 | 260,950 | Dec 23, 2024 |
| Dec 20, 2024 | Jon P Stonehouse President & CEO | GGift Common Stockindirect: By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust | +10,000 | $0.00 | $0 | 30,000 | Dec 23, 2024 |
| Dec 20, 2024 | Jon P Stonehouse President & CEO | GGift Common Stockindirect: By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust | +10,000 | $0.00 | $0 | 30,000 | Dec 23, 2024 |
| Dec 19, 2024 | Jon P Stonehouse President & CEO | AGrant or award Emp. Stock Option (Right to Buy)derivative | +750,250 | $0.00 | $0 | 750,250 | Dec 23, 2024 |
| Dec 14, 2024 | Helen M. Thackray Chief R&D Officer | FTax withholding Common Stock | -7,150 | $7.53 | $54k | 264,989 | Dec 17, 2024 |
| Dec 14, 2024 | Anthony Doyle Chief Financial Officer | FTax withholding Common Stock | -7,890 | $7.53 | $59k | 259,628 | Dec 17, 2024 |
| Dec 14, 2024 | Alane P Barnes Chief Legal Officer | FTax withholding Common Stock | -8,613 | $7.53 | $65k | 294,490 | Dec 17, 2024 |
| Dec 14, 2024 | Jon P Stonehouse President & CEO | FTax withholding Common Stock | -27,525 | $7.53 | $207k | 1,101,019 | Dec 17, 2024 |
| Dec 14, 2024 | Charles K Gayer Chief Commercial Officer | FTax withholding Common Stock | -8,251 | $7.53 | $62k | 300,057 | Dec 17, 2024 |
| Dec 13, 2024 | Nancy J Hutson director | SOpen-market sale Common Stock10b5-1 | -7,000 | $7.54 | $53k | 86,638 | Dec 16, 2024 |
| Nov 29, 2024 | Vincent Milano director | AGrant or award Common Stock | +750 | $7.50 | $5,625 | 76,084 | Dec 2, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Alane P BarnesChief Legal Officer
- Anthony DoyleChief Financial Officer
- Steven Frankdirector
- Charles K GayerChief Commercial Officer
- Nancy J Hutsondirector
- Vincent Milanodirector
- Amy E McKeedirector
- Jill C. Milneceo, president, officer, director
- Jon P StonehousePresident & CEO
- Helen M. ThackrayChief R&D Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.